KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind, a leader in medication management and personalized medicine through pharmacogenetics (PGx), is proud to announce the release of its innovative Patient Report. This new report empowers patients with easy-to-understand insights about how their genetics influence their body’s response to many medications. By making this information more accessible, the report fosters better collaboration between patients and healthcare providers, ensuring all parties are confident and informed about their treatment plans. The new Patient Report complements Genomind’s existing Neuropsych Report and Express Report already utilized by providers – creating an unmatched reporting suite for all audiences.
In the U.S., nearly five billion prescriptions are written each year for over 20,000 FDA-approved drugs. However, many of these medications are prescribed through a “trial and error” process, often leaving patients to experience preventable adverse drug events and unnecessary delays to better health. Genomind’s cutting-edge pharmacogenetic testing informs safer prescribing by providing genetic-based insights that inform medication decisions.
As pharmacogenetics is often unfamiliar to new patients, many may feel overwhelmed at first by the volume and depth of information provided by PGx testing. Although the test is ordered by a licensed healthcare provider, patients frequently struggle to interpret the results. Genomind’s Patient Report solves this problem. Utilizing a third-party research and consulting firm, Genomind achieved a 91% comprehension rate of its Patient Report with study participants and an over three-fold increase in their understanding of the field of pharmacogenetics. Utilizing common language, easy-to-navigate sections, and color-coded highlights, the Patient Report is simple to digest and incredibly readable – ensuring the power of pharmacogenetic testing is accessible for all.
“We understand that – while pharmacogenetic testing offers powerful insights – the information can sometimes feel overwhelming,” said Daniel Dowd, chief clinical officer at Genomind. “Our new Patient Report is designed to bridge that gap, offering key insights in streamlined, simple-to-understand language. With this new report, patients are empowered to be active consumers in their healthcare treatment decisions."
Key Aims of the Patient Report:
- Better Understanding: The report translates complex pharmacogenetic data into clear, actionable insights, helping patients understand how their genes may influence their body’s response to medications.
- Fosters Trust and Collaboration: Patients are better equipped to engage in meaningful conversations with their healthcare providers, leading to stronger collaboration around a shared treatment plan.
- Improved Patient Confidence: With simplified information, patients feel more informed and empowered to make decisions about their health.
- Patient Empowerment: By enabling patients to better understand their genetic profile, the report encourages active participation in treatment planning.
- Portability: The report is easy to share with other members of a patient’s care team, including specialists unfamiliar with pharmacogenetics.
Product Features Include:
- Clinical Insights: Clear explanations of how a patient’s genetic profile may influence their medication response.
- Actionable Data: Organizes gene effects and medications by class, making it easier for patients and providers to craft a personalized treatment plan consistent with published PGx guidelines.
- User-Friendly Design: With color-coded highlights, simple navigation, and an accessible format, the report is designed for patients of all backgrounds, regardless of familiarity with genetic testing.
- Side Effect Guidance: Provides insights into potential side effects based on a patient’s genetic makeup and medication history.
About Genomind
Genomind is at the forefront of personalized medicine, empowering healthcare providers with cutting-edge pharmacogenetic testing that informs medication decisions based on a patient’s unique genetic profile. By providing precise genetic insights, Genomind helps to optimize medication management, improving outcomes for patients and enhancing collaboration between patients and healthcare providers.
For more information about the Genomind Patient Report and how it’s revolutionizing personalized medication management, visit www.genomind.com.
